share_log

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga ·  Feb 19 21:05

Gainers

  • Autonomix Medical (NASDAQ:AMIX) stock rose 30.3% to $4.95 during Monday's pre-market session. The market value of their outstanding shares is at $93.0 million. As per the news, the Q3 earnings report came out 4 days ago.
  • Sarepta Therapeutics (NASDAQ:SRPT) stock increased by 12.64% to $140.68. The company's market cap stands at $13.1 billion.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 11.92% to $2.44. The company's market cap stands at $1.3 million.
  • Barinthus Biotherapeutics (NASDAQ:BRNS) shares moved upwards by 11.63% to $2.77. The market value of their outstanding shares is at $106.9 million.
  • Artivion (NYSE:AORT) shares increased by 10.86% to $20.0. The market value of their outstanding shares is at $820.9 million. As per the press release, Q4 earnings came out 2 days ago.
  • Calidi Biotherapeutics (AMEX:CLDI) shares rose 10.02% to $0.55. The company's market cap stands at $19.5 million.

Losers

  • Inventiva (NASDAQ:IVA) shares fell 15.2% to $3.34 during Monday's pre-market session. The company's market cap stands at $172.4 million.
  • Hepion Pharmaceuticals (NASDAQ:HEPA) stock declined by 12.97% to $2.35. The company's market cap stands at $10.1 million.
  • AMN Healthcare Services (NYSE:AMN) shares decreased by 12.35% to $68.05. The market value of their outstanding shares is at $2.5 billion. As per the news, the Q4 earnings report came out 2 days ago.
  • Brainstorm Cell (NASDAQ:BCLI) shares declined by 12.3% to $0.34. The market value of their outstanding shares is at $16.6 million.
  • Biophytis (NASDAQ:BPTS) shares decreased by 10.61% to $0.5. The company's market cap stands at $4.8 million.
  • Orgenesis (NASDAQ:ORGS) shares decreased by 8.75% to $0.44. The market value of their outstanding shares is at $13.9 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment